Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;19,391,6669:806–11. https://doi.org/10.1038/35888.

Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 2005;19(5):517–29. https://doi.org/10.1101/gad.1284105.

Article  CAS  PubMed  Google Scholar 

Bartel DP. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. https://doi.org/10.1016/s0092-8674(04)00045-5.

Article  CAS  PubMed  Google Scholar 

Crooke ST, Wang S, Vickers TM, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35(3):230–7.

Article  CAS  PubMed  Google Scholar 

Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40.

Article  CAS  PubMed  Google Scholar 

Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Kariko K. Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011;39(21):9329–38. https://doi.org/10.1093/nar/gkr586.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, Ian MacLachlan, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002–7.

Article  CAS  PubMed  Google Scholar 

Maier MA, Jayaraman M, Matsuda S, Liu Ju, Barros S, Querbes W, Tam YK, Ansell SM, Kumar V, Qin J, Zhang X, Wang Q, Panesar S, Hutabarat R, Carioto M, Hettinger J, Kandasamy P, Butler D, Rajeev KG, pang B, Charisse K, Fitzgerald K, Mui BL, Du X, Cullis P, Madden TD, Hope MJ, Manoharan M, and Akinc A,. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21(8):1570–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Therapeutic si RNA: state of the art. Signal Transduct Target Ther. 2020;5:101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Enders S, Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11:263–70.

Article  CAS  PubMed  Google Scholar 

Judge AD, Sood V, Shaw JR, Fang D, Mcclintock K, Maclachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457–62.

Article  CAS  PubMed  Google Scholar 

Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168(2):554–61.

Article  CAS  PubMed  Google Scholar 

Diebold SS, Kaisho T, Hemmi H, Akira S, Reise Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529–31.

Article  CAS  PubMed  Google Scholar 

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526–9.

Article  CAS  PubMed  Google Scholar 

Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000Prime Rep. 2014;4, 6, 97.

Weng Y, Xiao H, Zhang J, Liang XJ, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37(5):801–25.

Article  CAS  PubMed  Google Scholar 

Huang YY. Approval of the first-ever RNAi therapeutics and its technological development history. Prog Biochem Biophys. 2019;46(3):313–22.

Google Scholar 

Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15(185–197):26.

Google Scholar 

Liu J, Guo N, Gao C, Liu N, Zheng X, Tan Y, Lei J, Hao Y, Chen L, Zhang X. Effective gene silencing mediated by polypeptide nanoparticles LAH4-L1-siMDR1 in multi-drug resistant human breast cancer. J Biomed Nanotechnol. 2019;15(3):531–43.

Article  CAS  PubMed  Google Scholar 

Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18:3016–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sioud M, Furset G, Cekaite L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun. 2007;361(1):122–6.

Article  CAS  PubMed  Google Scholar 

Song X, Wang X, Ma Y, Liang Z, Zhenjun Y, Cao H. Site-specific modification using the 2′-methoxyethyl group improves the specificity and activity of siRNAs. Mol Ther Nucleic Acids. 2017;9:242–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–8.

Article  CAS  PubMed  Google Scholar 

Coelho T, Adam D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DWY, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–29.

Article  CAS  PubMed  Google Scholar 

Adams D, Ganzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante’-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Nochur SV, Sweetser M, Garg PP, Vaishnaw AK, Gollob JR and Suhr OB,. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. https://doi.org/10.1056/NEJMoa1716153.

Article  CAS  PubMed  Google Scholar 

Titze-de-Almeida R, David C, Titze-de-Almeida SS. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017;34(7):1339–63.

Article  CAS  PubMed  Google Scholar 

Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJC, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Kariko K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. Sequence and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452(7187):591–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75–83. https://doi.org/10.4137/OED.S4878.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang Xh, Seth PP, Crooke ST. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol. 2019;37:640–50.

Article  CAS  PubMed  Google Scholar 

Migawa MT, Shen W, Wan WB, Vasquez G, Oestergaard ME, Low A, De Hoyos CL, Gupta R, Murray S, Tanowitz M, Bell M, Nichols JG, Gaus H, Liang XH, Swayze EE, Crooke ST, Seth PP. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Res. 2019;47(11):5465–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marshall WS, Caruthers MH. Phosphorodithioate DNA as a potential therapeutic drug. Science. 1993;259:1564–70.

Article  CAS  PubMed  Google Scholar 

Ndeboko B, Ramamurthy N, Lemamy GJ, Jamard C, Nielsen PE, Cova L. Role of cell-penetrating peptidesin intracellular delivery of peptides nucleic acids targeting hepadnaviral replication. Mol Ther Nucleic Acids. 2017;9:162–9. https://doi.org/10.1016/j.omtn.2017.09.003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh RP, Oh BK, Choi JW. Application of peptide nucleic acid towards development of nanobiosensor arrays. Bioelectrochemistry. 2010;79:153–61.

Article  CAS  PubMed  Google Scholar 

Parmar R, Willoughby JLS, Liu J, Foster DJ, Bringham B, Theile CS, Charisse K, Akinc A, Guidry E, Pei Y, Strapps W, Cancilla M, Stanton MG, Rajeev KG, Sepp-Lorenzino L, Manoharan M, Meyers R, Maier MA, Jadhav V. 5′-(E)-vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. ChemBioChem. 2016;17(11):985–9.

Article  CAS  PubMed  Google Scholar